203 related articles for article (PubMed ID: 20166197)
21. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
[TBL] [Abstract][Full Text] [Related]
22. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
23. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
[TBL] [Abstract][Full Text] [Related]
24. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
Wong TW; Lee FY; Emanuel S; Fairchild C; Fargnoli J; Fink B; Gavai A; Hammell A; Henley B; Hilt C; Hunt JT; Krishnan B; Kukral D; Lewin A; Malone H; Norris D; Oppenheimer S; Vite G; Yu C
Clin Cancer Res; 2011 Jun; 17(12):4031-41. PubMed ID: 21531814
[TBL] [Abstract][Full Text] [Related]
25. Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects.
Vakkalagadda B; Park JS; Ahlers CM; Dorizio S; Has T; Roongta V; Heller KN; Derbin GM; Zhang S
J Clin Pharmacol; 2012 Sep; 52(9):1350-6. PubMed ID: 22031621
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.
Yang Z; Vakkalagadda B; Shen G; Ahlers CM; Has T; Christopher LJ; Kurland JF; Roongta V; Masson E; Zhang S
J Clin Pharmacol; 2013 Feb; 53(2):217-27. PubMed ID: 23436267
[TBL] [Abstract][Full Text] [Related]
27. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of the natural antibiotic negamycin.
Guo J; Miele EW; Chen A; Luzietti RA; Zambrowski M; Walsky RL; Buurman ET
Xenobiotica; 2015; 45(7):625-33. PubMed ID: 25733027
[TBL] [Abstract][Full Text] [Related]
29. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
[TBL] [Abstract][Full Text] [Related]
30. Biotransformation of the anti-angiogenic compound SU5416.
Antonian L; Zhang H; Yang C; Wagner G; Shawver LK; Shet M; Ogilvie B; Madan A; Parkinson A
Drug Metab Dispos; 2000 Dec; 28(12):1505-12. PubMed ID: 11095590
[TBL] [Abstract][Full Text] [Related]
31. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
32. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
Bhide RS; Cai ZW; Zhang YZ; Qian L; Wei D; Barbosa S; Lombardo LJ; Borzilleri RM; Zheng X; Wu LI; Barrish JC; Kim SH; Leavitt K; Mathur A; Leith L; Chao S; Wautlet B; Mortillo S; Jeyaseelan R; Kukral D; Hunt JT; Kamath A; Fura A; Vyas V; Marathe P; D'Arienzo C; Derbin G; Fargnoli J
J Med Chem; 2006 Apr; 49(7):2143-6. PubMed ID: 16570908
[TBL] [Abstract][Full Text] [Related]
33. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
[TBL] [Abstract][Full Text] [Related]
34. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist.
Bungay PJ; Tweedy S; Howe DC; Gibson KR; Jones HM; Mount NM
Drug Metab Dispos; 2011 Aug; 39(8):1396-405. PubMed ID: 21543556
[TBL] [Abstract][Full Text] [Related]
35. Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor.
Xiang H; McSurdy-Freed J; Moorthy GS; Hugger E; Bambal R; Han C; Ferrer S; Gargallo D; Davis CB
J Pharm Sci; 2006 Dec; 95(12):2657-72. PubMed ID: 16892205
[TBL] [Abstract][Full Text] [Related]
36. In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound.
S S; Vuppu S
J Pharm Biomed Anal; 2020 Feb; 179():113000. PubMed ID: 31787460
[TBL] [Abstract][Full Text] [Related]
37. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
39. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
40. Prodrugs of BMS-183920: metabolism and permeability considerations.
Obermeier MT; Chong S; Dando SA; Marino AM; Ryono DE; Starrett-Arroyo A; DiDonato GC; Warrack BM; White RE; Morrison RA
J Pharm Sci; 1996 Aug; 85(8):828-33. PubMed ID: 8863272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
